[8-K] Lantern Pharma Inc. Reports Material Event

Rhea-AI Filing Summary

Lantern Pharma Inc. reported in a Current Report on Form 8-K dated August 13, 2025 that it will issue a press release announcing its financial results for the second quarter ended June 30, 2025. The Company furnished the press release as Exhibit 99.1 and included a cover page interactive data file as Exhibit 104.

The filing notes the disclosure is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference into other filings. The document identifies Lantern Pharma as an emerging growth company, indicates it elected not to use the extended transition period for new accounting standards, lists its Nasdaq ticker LTRN, principal executive office in Dallas, Texas, and is signed by CFO David R. Margrave.

Positive

• Press release for Q2 2025 results was furnished as Exhibit 99.1, ensuring timely disclosure to the public.
• Interactive XBRL cover page (Exhibit 104) was included, supporting structured data access.

Negative

• The 8-K contains no financial figures or metrics; investors must wait for the press release text to assess results.
• Exhibit is furnished, not filed, so it is not subject to Section 18 liability and is not automatically incorporated by reference into other filings.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishing a press release for Q2 2025; no financial data in the filing, so immediate market impact is limited.

The Company has furnished (not filed) a press release as Exhibit 99.1 announcing results for the quarter ended June 30, 2025. Because the 8-K contains no financial figures or metrics, investors must review the furnished press release itself to assess revenue, earnings, cash position, or guidance. The filing clarifies legal treatment of the exhibit and confirms emerging growth company status, which may affect future reporting transition timelines.

Corporate Governance Expert

TL;DR: Proper procedural disclosure; furnishing exhibits limits Section 18 liability while providing timely information to the market.

The 8-K documents a standard disclosure practice: furnishing a press release (Exhibit 99.1) and including Inline XBRL cover page data (Exhibit 104). The Company explicitly states the exhibit is not "filed" for Section 18 purposes, preserving limited liability exposure. The filing also confirms the registrant's emerging growth company election and an affirmative choice not to use the extended transition period for new accounting standards.

false 0001763950 0001763950 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Lantern Pharma Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39318		46-3973463
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1920 McKinney Avenue, 7th Floor Dallas, Texas		75201
(Address of Principal Executive Offices)		(Zip Code)

(972) 277-1136

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Common Stock

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value		LTRN		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit Description
99.1		Press Release dated August 13, 2025 announcing financial results for quarter ended June 30, 2025.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

2 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Lantern Pharma Inc.,
	A Delaware Corporation
Dated: August 13, 2025	By:	/s/ David R. Margrave
		David R. Margrave, Chief Financial Officer

3 

FAQ

When will Lantern Pharma (LTRN) report Q2 2025 results?

The Form 8-K states the Company will issue a press release announcing financial results for the quarter ended June 30, 2025, and the report is dated August 13, 2025.

Where can I find the press release for Lantern Pharma's Q2 2025 results?

The press release is furnished as Exhibit 99.1 to the Form 8-K filed on August 13, 2025.

Is the press release considered "filed" under the Exchange Act?

No. The 8-K explicitly states the information and Exhibit 99.1 are furnished, not filed, and therefore are not subject to Section 18 liability or incorporated by reference into other filings.

Does Lantern Pharma identify as an emerging growth company?

Yes. The Form 8-K indicates Lantern Pharma is an emerging growth company and has checked the election regarding the extended transition period.

Who signed the Form 8-K for Lantern Pharma?

The report is signed by David R. Margrave, Chief Financial Officer of Lantern Pharma Inc.

What is Lantern Pharma's ticker and where is it listed?

Lantern Pharma's common stock trades under the ticker LTRN on The Nasdaq Stock Market.